GWP42003-P
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Infantile Spasms
Conditions
Infantile Spasms
Trial Timeline
May 12, 2017 → Jun 13, 2019
NCT ID
NCT02954887About GWP42003-P
GWP42003-P is a phase 3 stage product being developed by Jazz Pharmaceuticals for Infantile Spasms. The current trial status is completed. This product is registered under clinical trial identifier NCT02954887. Target conditions include Infantile Spasms.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04485104 | Phase 3 | Terminated |
| NCT04133480 | Approved | Withdrawn |
| NCT04252586 | Phase 3 | Terminated |
| NCT02954887 | Phase 3 | Completed |
| NCT02953548 | Phase 3 | Completed |
| NCT02607904 | Phase 2 | Completed |
| NCT02544750 | Phase 3 | Completed |
Competing Products
16 competing products in Infantile Spasms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TSHA-101 | Taysha Gene Therapies | Phase 1/2 | 36 |
| MAS825 + Placebo | Novartis | Phase 2 | 52 |
| alglucosidase alfa + alglucosidase alfa | Sanofi | Approved | 84 |
| Myozyme | Sanofi | Phase 2 | 51 |
| Bacillus Clausii Multi ATB Resist + Placebo | Sanofi | Approved | 84 |
| Radiprodil | UCB | Phase 2 | 49 |
| Larotrectinib (Vitrakvi, BAY2757556) + Standard of Care | Bayer | Pre-clinical | 20 |
| Sabril® | Lundbeck | Pre-clinical | 20 |
| Vigabatrin | Lundbeck | Approved | 82 |
| Nusinersen | Biogen | Pre-clinical | 20 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |
| Cerliponase Alfa | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Cholic Acids | Mirum Pharmaceuticals | Phase 3 | 74 |
| Cipaglucosidase alfa + Miglustat | Amicus Therapeutics | Phase 3 | 74 |
| ATB200 + AT2221 | Amicus Therapeutics | Pre-clinical | 20 |
| RP-L401 | Rocket Pharmaceuticals | Phase 1 | 25 |